- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
- Interventions
- Ambrisentan, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 255
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Idiopathic Pulmonary Fibrosis, Healthy
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- ACT-064992 (macitentan), Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
- Interventions
- Bardoxolone methyl, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more
- Conditions
- Pulmonary Fibrosis
- Interventions
- pomalidomide (CC-4047
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Ann Arbor, Michigan • Dallas, Texas + 1 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- HRCT, Blood Draw
- Diagnostic Test
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 40 Years to 101 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
- Interventions
- Surgery
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Not listed
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
- Interventions
- Interferon gamma-1b
- Drug
- Lead sponsor
- InterMune
- Industry
- Eligibility
- Not listed
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
- Interventions
- Sildenafil, Losartan, Sildenafil and Losartan, Placebo Oral Tablet
- Drug
- Lead sponsor
- Alicia Gerke
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Interferon-gamma 1b
- Drug
- Lead sponsor
- InterMune
- Industry
- Eligibility
- 20 Years to 79 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Placebo, Pirfenidone, Deupirfenidone
- Drug
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 19 more
- Conditions
- Cough, Idiopathic Pulmonary Fibrosis
- Interventions
- Orvepitant Maleate, Placebo
- Drug
- Lead sponsor
- Nerre Therapeutics Ltd.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more
- Conditions
- Interstitial Lung Disease
- Interventions
- Not listed
- Lead sponsor
- Pulmonary Care and Research Collaborative Limited
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
- Interventions
- Riociguat (Adempas, BAY63-2521), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 17
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Buloxibutid, Placebo
- Drug
- Lead sponsor
- Vicore Pharma AB
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Redding, California • Sacramento, California + 19 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- CHF10067, Placebo
- Drug · Other
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Hannibal, Missouri • Denison, Texas
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
- Interventions
- sildenafil
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- AZD5055, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
- Interventions
- Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
- Biological
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 2 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 15 more
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34,960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Ridgefield, Connecticut
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Metformin, Matching Placebo
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more